Navigation Links
Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
Date:5/31/2010

SAN FRANCISCO, CA/ATLANTA, GA, June 1, 2010 - Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

Evaluating a combined total of 556 (randomized) and 536 (treated) men with primary PE in the United States, Canada and Europe over a three-month period, with more than 23,000 exposures to PSD502 recorded, the data demonstrated that men who were treated with PSD502 five minutes before intercourse by applying PSD502 via a topical metered dose spray had a time to ejaculation 5.5 times longer than those who used a placebo spray with the actual average measurement in minutes for drug and placebo.

A co-primary endpoint also looked at ejaculatory control and satisfaction. Point differences of 6.1 and 5.3 were observed between the PSD502 group and placebo in ejaculatory control and satisfaction domains, respectively (p<0.0001 for all).

"Combined results from the PSD502 pivotal studies are very exciting and this is a significant milestone," said Ira D. Sharlip, MD, clinical trial investigator and clinical professor of urology at the University of California, San Francisco.

The exact incidence of PE is not known, as a widely accepted definition of PE has only recently become available. Depending on the definition used, ranges from 5% to more than 30% incidence of PE or ejaculatory control issues have been reported in the literature. For example, according to a large national study, approximately 30% of men suffer from ejaculatory control issues, including climaxing too early, while data from the National Health and Social Life Survey (NHSLS) states the prevalence as 21% in men ages 18 to 59 in the Un
'/>"/>

Contact: Dave Schemelia
dschemelia@healthstarpr.com
609-468-9325
HealthStar PR
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
2. Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
3. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
4. BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment
5. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
6. Steroids May Be Overrated in Treatment of COPD
7. Experimental stem cell treatment arrests acute lung injury in mice, study shows
8. Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
9. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
10. New York City Surgeon Develops All-Natural Treatment for Wrinkles and Scars
11. Novelty lures rats from cocaine-paired settings, hinting at new treatments for recovering addicts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing, is proud to ... for EKG interpretation of athletes. , ... death during athletic activity. New findings presented in February ... to improve cardiac safety in athletes. Physiologic adaptations in ...
(Date:5/29/2015)... 29, 2015 Thursday, May 21st was the ... from all walks of life came together to raise money ... Day is a campaign dedicated to raising money for children ... and making people laugh, the people at Hands-On Seminars decided ... Here they provided food, fun and laughter to their ...
(Date:5/29/2015)... 2015 Belviq for weight loss ... prescription diet medication. In 2012, the FDA approved ... have a BMI >30. It is also approved ... one additional weight-related health condition such as high blood ... main function for weight loss focuses on the brain’s ...
(Date:5/28/2015)... External Counterpulsation (EECP/ECP) has been used ... United States. There are a growing number of people ... symptoms of angina and these patients are often times ... surgery. , “No option” patients are a sizable cohort ... that is considered unacceptable for heart stent or bypass. ...
(Date:5/28/2015)... May 28, 2015 AMVETS National Executive ... the Commission on Care established by Congress to examine ... veterans. , Appointed to the commission by Mitch McConnell, ... be one of only 15 voting members on the ... and Accountability Act of 2014. The goal of the ...
Breaking Medicine News(10 mins):Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2
... ... TV 4 recently awarded Dr. Michael Macdonald of the Aesthetic Surgery Center ... awards. Dr. Macdonald is one of the few cosmetic surgeons in the ... and Reconstructive Surgery and Head and Neck Surgery. ,With over 20 years ...
... ... of successes in its Wide Format Digital Printing and ID Badge divisions. , ... Memphis, TN (PRWEB) April ... despite the tough economy. The company’s two distinct product divisions, Wide Format Digital Printing ...
... ... 2010 targets in the fight against the disease, World Vision’s End Malaria campaign is leading ... to press American congressional leaders to keep investing in programs that are saving the lives ... ...
... ... rash-inducing plants are growing faster and producing more potent toxins as compared ... create ideal conditions for these poisonous plants, producing larger and faster growth ... plants, the topical reactions become worse and affect a larger population, but ...
... ... or associated risk factors, today introduced ,How Your Brain Can Save Your Heart (And ... has shown to be critical for making permanent lifestyle changes that increase our prospects ... ...
... ... and American Society of Pain Educators to pursue publishing and teaching opportunities. , ... (PRWEB) April 16, 2010 ... management education and producers of PAINWeek ( www.painweek.org ) — the national ...
Cached Medicine News:Health News:Dr. Michael Macdonald Named Best Plastic Surgeon in San Francisco Bay Area 2Health News:Dr. Michael Macdonald Named Best Plastic Surgeon in San Francisco Bay Area 3Health News:LSI Earns 3M Warranty Certification; Gains Federal ID Badge Contracts 2Health News:LSI Earns 3M Warranty Certification; Gains Federal ID Badge Contracts 3Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 2Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 3Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 2Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 3Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 4Health News:HeartCoaches Introduces Brain-Based Strategies for a Healthy Heart 2Health News:HeartCoaches Introduces Brain-Based Strategies for a Healthy Heart 3Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 2Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 3
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies Ltd. ... medical technologies company, is delighted to announce its ... 31, 2015, which includes revenue for three months ... of $264,340. Revenue from advanced wound care product sales ... 2015 increased 24% to $1,742,672 compared to $1,400,065 ...
(Date:5/29/2015)... 29, 2015  Epic Sciences announced today that the ... metastatic castrate resistant prostate cancer patients, at the ... Clinical Oncology. This application expands the investigational utility ... platform to characterize circulating tumor cell (CTC) ... patients have heterogeneous clonal CTC populations harboring separate ...
(Date:5/29/2015)... NEW YORK , May 29, 2015  World-renowned prostate ... evaluates new findings on the benefit of MR/Ultrasound Fusion-Guided ... "Our Prostate Cancer Center at Lenox ... MR/Ultrasound Fusion Biopsy System in New York City ... high and low risk prostate cancers. The use of an ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 2Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity 3MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2
... 2011 Savvy executives in pharmaceutical commercial functions ... in today,s volatile healthcare environment. Quantitative and qualitative ... for increased resources, justify costs, or signal necessary ... presidents, directors, and managers tasked with right-sizing investment ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... European Medicines Agency (EMA) has granted orphan designation for ... B. Orphan designation in the European Union provides several ... launch and access to the central authorization procedure. ...
Cached Medicine Technology:Pharmaceutical Investment & Cost Benchmarks Accessed Quickly Through Best Practices, LLC's New Database Search Function 2Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: